RxDoctor Payments Data

Christine Gearhart

Family · Radnor, PANPI 1174572622

Payments from drug & device makers

$2,168in general payments, 2019–2025

Across 54 payments — averaging $40.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$698
  • Boston Scientific$445
  • Averitas Pharma Inc.$221
  • Collegium Pharmaceutical, Inc.$185
  • Vertos Medical, Inc.$139
  • Scilex Pharmaceuticals Inc.$138
  • plus $342 from 10 others

What the payments were for

  • Food & beverage$2,13699%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,168 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$102,436
Medicare patients
239
Services billed
972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl89$70,422
WegovySemaglutide29$38,659
OzempicSemaglutide32$37,337
ZtlidoLidocaine37$36,437
Buprenorphine86$28,701
Pregabalin200$5,602
Gabapentin237$3,732
Celecoxib67$3,606
Lidocaine31$3,383
Naloxone Hcl32$2,188
Tramadol Hcl ErTramadol Hcl39$1,993
Duloxetine Hcl105$1,691
Tizanidine Hcl147$1,431
Tramadol Hcl157$1,142
Oxycodone Hcl77$1,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskWegovy, Ozempic$698$75,99661 claims
Collegium Pharmaceutical, Inc.Belbuca$185$70,42289 claims
Scilex Pharmaceuticals Inc.Ztlido$138$36,43737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in Radnor

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →